AHR and cancer: It was not until recently that the role of TDO in cancer was appreciated, when emerging evidence showed that TDO, but not IDO1, is the central Trp-degrading enzyme in human glioma cells, and that the TDO–AhR pathway was associated with malignant progression and poor survival for this tumor (Opitz et al., 2011).